303 related articles for article (PubMed ID: 30501497)
1. Bumetanide for Autism Spectrum Disorder in Children: A Review of Randomized Controlled Trials.
James BJ; Gales MA; Gales BJ
Ann Pharmacother; 2019 May; 53(5):537-544. PubMed ID: 30501497
[TBL] [Abstract][Full Text] [Related]
2. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.
Lemonnier E; Villeneuve N; Sonie S; Serret S; Rosier A; Roue M; Brosset P; Viellard M; Bernoux D; Rondeau S; Thummler S; Ravel D; Ben-Ari Y
Transl Psychiatry; 2017 Mar; 7(3):e1056. PubMed ID: 28291262
[TBL] [Abstract][Full Text] [Related]
3. Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
Crutel V; Lambert E; Penelaud PF; Albarrán Severo C; Fuentes J; Rosier A; Hervás A; Marret S; Oliveira G; Parellada M; Kyaga S; Gouttefangeas S; Bertrand M; Ravel D; Falissard B
J Autism Dev Disord; 2021 Aug; 51(8):2959-2972. PubMed ID: 33151500
[TBL] [Abstract][Full Text] [Related]
4. Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.
Fuentes J; Parellada M; Georgoula C; Oliveira G; Marret S; Crutel V; Albarran C; Lambert E; Pénélaud PF; Ravel D; Ben Ari Y
Autism Res; 2023 Oct; 16(10):2021-2034. PubMed ID: 37794745
[TBL] [Abstract][Full Text] [Related]
5. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial.
Dai Y; Zhang L; Yu J; Zhou X; He H; Ji Y; Wang K; Du X; Liu X; Tang Y; Deng S; Langley C; Li WG; Zhang J; Feng J; Sahakian BJ; Luo Q; Li F
Sci Bull (Beijing); 2021 Aug; 66(15):1591-1598. PubMed ID: 36654288
[TBL] [Abstract][Full Text] [Related]
6. Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder.
Shaker E; El Agami O; Salamah A
CNS Neurol Disord Drug Targets; 2024; 23(4):536-542. PubMed ID: 37021422
[TBL] [Abstract][Full Text] [Related]
7. Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial.
Sprengers JJ; van Andel DM; Zuithoff NPA; Keijzer-Veen MG; Schulp AJA; Scheepers FE; Lilien MR; Oranje B; Bruining H
J Am Acad Child Adolesc Psychiatry; 2021 Jul; 60(7):865-876. PubMed ID: 32730977
[TBL] [Abstract][Full Text] [Related]
8. Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial.
Lee SH; Shin S; Kim TH; Kim SM; Do TY; Park S; Lee B; Shin HJ; Lee J; Lee JY; Chang GT
Trials; 2019 Jul; 20(1):434. PubMed ID: 31307524
[TBL] [Abstract][Full Text] [Related]
9. Successive clinical application of vitamin D and bumetanide in children with autism spectrum disorder: A case report.
Feng JY; Li HH; Wang B; Shan L; Jia FY
Medicine (Baltimore); 2020 Jan; 99(2):e18661. PubMed ID: 31914053
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder.
Saad K; Abdel-Rahman AA; Elserogy YM; Al-Atram AA; El-Houfey AA; Othman HA; Bjørklund G; Jia F; Urbina MA; Abo-Elela MGM; Ahmad FA; Abd El-Baseer KA; Ahmed AE; Abdel-Salam AM
J Child Psychol Psychiatry; 2018 Jan; 59(1):20-29. PubMed ID: 27868194
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-Based Medications.
Vitiello B
J Am Acad Child Adolesc Psychiatry; 2021 Jul; 60(7):816-817. PubMed ID: 33212159
[TBL] [Abstract][Full Text] [Related]
12. A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism.
Du L; Shan L; Wang B; Li H; Xu Z; Staal WG; Jia F
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):585-8. PubMed ID: 26258842
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder.
Juarez-Martinez EL; Sprengers JJ; Cristian G; Oranje B; van Andel DM; Avramiea AE; Simpraga S; Houtman SJ; Hardstone R; Gerver C; Jan van der Wilt G; Mansvelder HD; Eijkemans MJC; Linkenkaer-Hansen K; Bruining H
Biol Psychiatry Cogn Neurosci Neuroimaging; 2023 Mar; 8(3):251-261. PubMed ID: 34506972
[TBL] [Abstract][Full Text] [Related]
14. Treatment Effect of Bumetanide in Children With Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.
Wang T; Shan L; Miao C; Xu Z; Jia F
Front Psychiatry; 2021; 12():751575. PubMed ID: 34867539
[No Abstract] [Full Text] [Related]
15. Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios.
Zhang L; Huang CC; Dai Y; Luo Q; Ji Y; Wang K; Deng S; Yu J; Xu M; Du X; Tang Y; Shen C; Feng J; Sahakian BJ; Lin CP; Li F
Transl Psychiatry; 2020 Jan; 10(1):9. PubMed ID: 32066666
[TBL] [Abstract][Full Text] [Related]
16. A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.
Georgoula C; Ferrin M; Pietraszczyk-Kedziora B; Hervas A; Marret S; Oliveira G; Rosier A; Crutel V; Besse E; Severo CA; Ravel D; Fuentes J
Child Psychiatry Hum Dev; 2023 Oct; 54(5):1360-1372. PubMed ID: 35292925
[TBL] [Abstract][Full Text] [Related]
17. The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder.
Li Q; Zhang L; Shan H; Yu J; Dai Y; He H; Li WG; Langley C; Sahakian BJ; Yao Y; Luo Q; Li F
Transl Psychiatry; 2022 Jun; 12(1):228. PubMed ID: 35660740
[TBL] [Abstract][Full Text] [Related]
18. Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.
van Andel DM; Sprengers JJ; Oranje B; Scheepers FE; Jansen FE; Bruining H
Mol Autism; 2020 May; 11(1):30. PubMed ID: 32381101
[TBL] [Abstract][Full Text] [Related]
19. Effect of L-Carnosine in children with autism spectrum disorders: a systematic review and meta-analysis of randomised controlled trials.
Abraham DA; Undela K; Narasimhan U; Rajanandh MG
Amino Acids; 2021 Apr; 53(4):575-585. PubMed ID: 33704575
[TBL] [Abstract][Full Text] [Related]
20. Multiple Antipsychotic Medication Use in Autism Spectrum Disorder.
Wink LK; Pedapati EV; Horn PS; McDougle CJ; Erickson CA
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):91-94. PubMed ID: 26465194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
